OncRef

Clinical Trial: NCT03945773

Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors

Status:

COMPLETED

Phase:

Phase 2

Lead Sponsor:Ipsen
Information Provided By:Ipsen
Last Update Posted:2026-10-06

Study Overview

Brief Summary

The overall objective of this study is to evaluate the efficacy and safety of cabozantinib as 2nd line treatment in subjects with unresectable, locally advanced or metastatic RCC with a clear-cell component, who progressed after prior Checkpoint Inhibitors (CPI) therapy with ipilimumab and nivolumab in combination or CPI combined with Vascular Endothelial Growth Factor (VEGF)-targeted therapy.

Official Title

A Phase II, Multicentre, Open-label Study of Cabozantinib as 2nd Line Treatment in Subjects With Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors.

Conditions

Locally Advanced or Metastatic Renal Cell Carcinoma

Intervention / Treatment

  • Drug: Cabozantinib

Other Study ID Numbers

  • F-FR-60000-023
  • 2018-002820-18
  • 2024-514479-16-00
  • 2018

Start Date (Actual)

2020-01-08

Primary Completion Date (Actual)

2023-05-11

Study Completion Date (Actual)

2026-02-12

Enrollment (Actual)

127

Study Type

Interventional

Phase

Phase 2